Emcure Pharmaceuticals Limited share price
NSE: EMCURE · ISIN INE168P01015
Key numbers
- Market cap
- ₹ 37,005 Cr
- Current price
- ₹ 1,950.60
- 52-week high / low
- ₹ 2,101 / 1,260
- Stock P/E
- 36.5
- Book value
- ₹ 261.1
- Dividend yield
- 0.18%
- ROCE
- 23.6%
- ROE
- 19.7%
- Debt to equity
- 0.31
- Sales growth (3 yrs)
- 15.4%
- Profit growth (3 yrs)
- 20.2%
- 1-year return
- 46.7%
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 2,101 | 2,270 | 2,363 | 2,470 | 2,580 |
| Operating profit | 404 | 439 | 460 | 485 | 508 |
| Net profit | 207 | 243 | 231 | 243 | 294 |
| EPS (₹) | 10.92 | 12.85 | 12.16 | 12.84 | 15.50 |
Investor presentation summary (2026-09-25)
AI summary of the presentation · tone: Positive · source document
Key numbers
- Gross Profit Margin 60.3% 60.1% 20 bps
- EBITDA Margin 19.4% 18.6% 80 bps
Guidance & outlook
- Financials FY26 and Q1 FY27
- ▲ 17.6% CAGR over FY24–FY26
Growth & demand
- A diversified growth platform with earnings growth ahead of revenue
- Priority franchises, productivity and differentiated launches are the principal India growth levers
Margins & costs
- EBITDA* (INR Mn) and margin (%)
- 03 Utilisation Improve capacity utilisation and asset productivity
Capex & expansion
- Such statements may include, but are not limited to, references to Emcure's business strategy, expansion plans, R&D pipeline, regulatory
- Blackstone's first investment in
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.